Evolus Inc EOLS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Evolus Reports Third Quarter 2026 Financial Results with 13% Year-Over-Year Revenue Growth; Delivers Fourth Consecutive Quarter of Positive Adjusted EBITDA and Reaffirms Full-Year 2026 Financial Outlook
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Evolus to Participate in Upcoming Investor Conferences in New York and London
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Evolus, Inc. - EOLS
Evolus to Report Third Quarter Financial Results on November 4, 2026
Trading Information
- Previous Close Price
- $7.07
- Day Range
- $6.93–7.21
- 52-Week Range
- $3.86–9.31
- Bid/Ask
- $6.15 / $7.77
- Shares Outstanding
- 66.19M
- Market Cap
- $463.32M
- Volume/Avg
- 870,976 / 918,971
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.42
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 365
- Website
- https://www.evolus.com
Valuation
Metric | EOLS |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 1.42 |
Price/Cash Flow | 87.51 |
Price/Earnings
No chart available
Financial Strength
Metric | EOLS |
|---|---|
Quick Ratio | 1.09 |
Current Ratio | 1.70 |
Interest Coverage | −0.92 |
Quick Ratio
EOLS
Profitability
Metric | EOLS |
|---|---|
Return on Assets (Normalized) | −5.99% |
Return on Equity (Normalized) | — |
Return on Invested Capital (Normalized) | −2.29% |
Return on Assets
EOLS
Drug Manufacturers - Specialty & Generic Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Merck KGaA ADR MKKGY | LOCK|#ysD&kL | LOCK|clTq | $71B | |||
| Teva Pharmaceutical Industries Ltd TEVA | LOCK|^$vN%^Y> | LOCK|GfT> | $47B | |||
| Haleon PLC ADR HLN | LOCK|Lj!yR# | LOCK|gw^ | $39B | |||
| Zoetis Inc Class A ZTS | LOCK|#$S<nCN | LOCK|hs | $33B | |||
| Viatris Inc VTRS | LOCK|Q$Vqct@ | LOCK|GJ@ | $23B | |||
| Elanco Animal Health Inc ELAN | LOCK|cx | LOCK|!$j | $13B | |||
| Dr Reddy's Laboratories Ltd ADR RDY | LOCK|!R^@GxW | LOCK|!ll | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A HIMS | LOCK|Lg<XWn | LOCK|kb# | $4B | |||
| Prestige Consumer Healthcare Inc PBH | LOCK|@xk<&q | LOCK|ybxq^ | $2B | |||
| Perrigo Co PLC PRGO | LOCK|^Wcx<VZ | LOCK|tV | $2B |